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OBJECTIVES We investigated the safety and pharmacodynamics of escalating doses of recombinant
nematode anticoagulant protein c2 (rNAPc2) in patients undergoing elective coronary
angioplasty.
BACKGROUND Recombinant NAPc2 is a potent inhibitor of the tissue factor/factor VIIa complex, which has
the potential to reduce the risk of thrombotic complications in coronary artery disease.
METHODS In a randomized, double-blinded, dose-escalation, multicenter trial, 154 patients received
placebo or rNAPc2 at doses of 3.5, 5.0, 7.5, and 10.0 g/kg body weight as a single
subcutaneous administration 2 to 6 h before angioplasty. All patients received aspirin,
unfractionated heparin during angioplasty, and clopidogrel in case of stent implantation.
RESULTS Minor bleeding rates for the doses 3.5 to 7.5 g/kg were comparable to that with placebo
(6.7%), whereas an incidence of 26.9% was observed at the 10.0-g/kg dose level (p  0.01).
Major bleedings occurred in the 5.0-g/kg (n  3) and 7.5-g/kg (n  1) dose groups. The
three patients in the 5.0-g/kg dose group also received a glycoprotein IIb/IIIa receptor
inhibitor at the moment of major bleeding. Systemic thrombin generation, as measured by
prothrombin fragment 12 (F12), was suppressed in all rNAPc2 dose groups to levels below
pretreatment values for at least 36 h. In the placebo group, a distinct increase of F12 levels
was observed following cessation of heparin.
CONCLUSIONS Inhibition of the tissue factor/factor VIIa complex with rNAPc2, at doses up to 7.5 g/kg,
in combination with aspirin, clopidogrel, and unfractionated heparin appears to be a safe and
effective strategy to prevent thrombin generation during coronary angioplasty. (J Am Coll
Cardiol 2003;41:2147–53i) © 2003 by the American College of Cardiology Foundation
Tissue factor (TF) is a significant component of atheroscle-
rotic plaques and is thought to be the primary trigger of
thrombosis following plaque rupture in patients with unsta-
ble coronary syndromes (1–3). When exposed to blood, TF
forms a high-affinity complex with circulating factor VIIa
(TF/factor VIIa) that initiates the coagulation cascade
through activation of factors IX and X, leading to the
formation of thrombin and subsequent thrombosis (4).
Consequently, inhibitors of TF/factor VIIa have been eval-
uated for their potential to reduce coronary thrombosis in
experimental studies of thrombosis (5–7).
Recombinant nematode anticoagulant protein c2
(rNAPc2) is an 85-amino-acid protein that was isolated
from the hemophagocytic hookworm Ancylostoma caninum
(8). It specifically inhibits the complex TF/factor VIIa by a
unique mechanism that involves the formation of a high-
affinity complex with zymogen or activated factor X prior to
formation of the quaternary inhibitory complex with TF/
factor VIIa (9). Utilization of zymogen factor X as an
inhibitory scaffold obviates the need for generating activated
factor X to inhibit the TF/factor VIIa complex. Theoreti-
cally, this should result in rapid and efficient inhibition of
TF/factor VIIa by rNAPc2 following a thrombogenic chal-
lenge. To this point, rNAPc2 has been shown to be very
effective in reducing the incidence of deep venous throm-
bosis without hemostatic compromise when administered
prophylactically in patients undergoing knee arthroplasty
(10). In addition, the formation of a complex with factor X
results in a biologic half-life of rNAPc2 of 50 h.
The importance of TF/factor VIIa in coronary thrombo-
sis suggests that rNAPc2 could be effective in the treatment
of patients with acute coronary syndromes. As the majority
of these patients undergo percutaneous coronary interven-
tions (PCIs), we first performed a phase II, dose-ranging
study with four escalating dosages of rNAPc2 in patients
undergoing elective coronary angioplasty to evaluate the
safety of the drug and its ability to inhibit thrombin
generation.
METHODS
Patients. Five centers in the Netherlands enrolled patients
between 18 and 80 years of age, with a history of stable
angina and scheduled for elective PCI of one or two lesions
with 50% diameter stenosis. Exclusion criteria included
total occlusion, unstable angina or myocardial infarction
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(MI) within 14 days, a recent history of surgery, trauma,
cardiopulmonary resuscitation, confirmed peptic ulcer, a
previous history of abnormal bleeding, uncontrolled hyper-
tension, renal or hepatic insufficiency, and treatment with or
intended use of oral antithrombotic agents other than
aspirin and clopidogrel during the study period. Planned use
of glycoprotein (GP) IIb/IIIa receptor antagonists was
excluded because there was no information available regard-
ing the potential interaction of rNAPc2 with these agents.
The study protocol was conducted according to the
International Conference on Harmonisation Good Clinical
Practice Guidelines (11) and approved by the institutional
review boards. Written, informed consent was obtained
from all patients.
Study design. This study was designed as a randomized,
placebo-controlled, double-blinded, multicenter study to
evaluate the safety of rNAPc2 in addition to standard
treatment during PCI. Patients were randomized to receive
treatment with rNAPc2 or placebo in a ratio of 4:1,
respectively, in each dose group. As a dose group consisted
of 30 patients, this resulted in 24 patients per group
treated with rNAPc2 and6 patients who received placebo.
All placebo-assigned patients in each dose group were
clustered into one placebo group. After randomization,
patients received a single subcutaneous dose of rNAPc2 or
placebo 2 to 6 h before PCI. The dosing of rNAPc2 was
such that maximal levels were reached during PCI. After
access to the femoral artery, unfractionated heparin (UFH)
was administered as intravenous bolus injections to reach an
activated clotting time 250 s throughout the intervention.
Sheath (5F or 6F) removal after PCI was performed as soon
as an activated clotting time 180 s was reached. Patients
were hospitalized for 36 h after dosing, and follow-up
consisted of a telephone interview at 48 h and a clinical
assessment at two weeks. The four doses of rNAPc2 tested
sequentially were 3.5, 5.0, 7.5, and 10.0 g/kg body weight.
Each increase in dose was dependent on review by an
independent Data Safety Monitoring Committee. All pa-
tients received at least 80 mg/day aspirin throughout the
study. If stent implantation was performed, a loading dose
of 300 mg clopidogrel was administered, followed by 75
mg/day for at least three weeks. Patients receiving a stent in
the initial 3.5-g/kg rNAPc2 dose group were given clopi-
dogrel after sheath removal as an additional safety measure
at the start of the trial. After successful completion of this
dose group, the protocol was amended, allowing clopidogrel
administration within three days prior to the intervention to
reflect current practice. Subsequently, a second 3.5-g/kg
dose group was completed. This led to a total of six
treatment groups: one placebo and five rNAPc2 (3.5, 3.5,
5.0, 7.5, and 10.0 g/kg).
Blood collection and assays. Six blood samples were taken
from each patient during hospitalization–that is, before
administration of the study drug, after access to the femoral
artery but before angioplasty, at 2 and 8 h after the last bolus
administration of UFH, and at 24 and 36 h after study drug
administration. Blood was collected in citrated vacutainer
tubes and immediately centrifuged at 4°C. Plasma samples
were stored at 70°C until assayed.
Thrombin generation was quantified as prothrombin
fragment 12 (F12) and thrombin/antithrombin (TAT)
complexes by using the enzyme-linked immunosorbent
assay (ELISA) for both measurements (Behringwerke AG,
Marburg, Germany). Normal values ranged from 0.4 to 1.1
nmol/l for F12 and from 1.0 to 4.1 g/l for TAT
complexes. For plasma concentrations between 0.4 and 5.0
nmol/l of F12 and between 2.0 and 60.0 g/l of TAT
complexes, the intra-assay coefficient of variations varied
between 5.0% and 7.5%, and between 4.0% and 6.0%,
respectively. The plasma concentrations of rNAPc2 were
also analyzed by ELISA (Corvas International, San Diego,
California).
Study outcomes and definitions. The primary safety out-
come of the study was the incidence of bleeding complica-
tions. A major bleeding episode was defined as clinically
overt bleeding resulting in death; retroperitoneal, intracra-
nial, or critical internal organ bleeding; a hemoglobin drop
of 3 g/dl; or the requirement of transfusion of 2 units of
blood. A minor bleed was any clinically significant bleeding
that did not qualify as major, such as epistaxis, ecchymosis,
macroscopic hematuria, puncture-site bleedings such as
groin hematoma measuring 100 cm2, or any other located
hematoma. Groin hematoma size was determined by esti-
mation of the surface area.
A secondary pharmacodynamic outcome was the extent
of systemic thrombin generation performed by serial mea-
surements of plasma levels of F12 and TAT complexes.
Myocardial infarction was defined as a creatine kinase,
MB fraction concentration of more than three times the
upper limit of normal.
We introduced a new quantitative safety measurement for
puncture-site (surgical) hemostasis—femoral compression
time (FCT), defined as the groin compression time (in
minutes) between sheath removal from the femoral artery
and achievement of complete hemostasis. This required
manual groin compression just proximal to the puncture site
by experienced personnel, using a standardized method
described in the protocol. Continuous manual compression
Abbreviations and Acronyms
F12  prothrombin activation fragment 12
FCT  femoral compression time
GP  glycoprotein
IQR  interquartile range
MI  myocardial infarction
PCI  percutaneous coronary intervention
rNAPc2  recombinant nematode anticoagulant
protein c2
TAT  thrombin/antithrombin complexes
TF  tissue factor
UFH  unfractionated heparin
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was mandated for the first 10 min, followed by release, and
if hemostasis was complete, FCT was recorded as 10 min. If
not, compression was re-instituted for periods of 3 min until
complete hemostasis, which was defined as no discernible
bleeding externally or internally by careful inspection for at
least 1 min.
Statistical analysis. Descriptive statistics included mean
values  SD or median values with interquartile ranges
(IQR) for outcomes with or without a normal distribution,
respectively. Distribution of the variables was analyzed by
construction of histograms and by the Shapiro-Wilk W test.
A p value 0.05 was considered significant. Differences
between each rNAPc2 dose group and the placebo group
were tested for all study outcomes. A comparison of baseline
and procedural characteristics, clinical events, and minor
and major bleeding incidences was made by chi-square
analysis for categorical variables and by either the unpaired
Student t test or Mann-Whitney U test for continuous
variables, as appropriate. Regarding thrombin generation
markers, the treatment groups were compared for each time
point separately by means of one-way analyses of variance
and subsequent pairwise comparisons with placebo, with
Bonferroni correction. Spearman correlation was computed
between FCT and rNAPc2 plasma levels at the moment of
sheath removal, and between plasma levels of rNAPc2 and
markers of thrombin generation after PCI. All statistical
analyses were performed with SPSS version 10.1 (Chicago,
Illinois).
RESULTS
Patients. A total of 154 patients were randomized to one of
four rNAPc2 dosages or placebo. Baseline characteristics are
shown in Table 1. No significant differences were found
between each rNAPc2 treatment group and the placebo
group, except for gender in the second 3.5-g/kg dose
group.
Procedural characteristics. Procedural characteristics are
presented in Table 2. The mean time between study drug
administration and access to the femoral artery was 3.4 
1.4 h. Clopidogrel was administered in 74% of the study
population. In 28% of these patients, clopidogrel was started
prior to PCI, with no differences between placebo and each
rNAPc2 dose group.
Femoral compression time was evaluated in 149 patients
(97%). Compression time was not measured in four pa-
tients, and one patient was excluded because PCI and
sheath removal were performed 24 h after study drug
administration. Introduction of the sheath into the femoral
artery was uneventful in all patients except one, who
required multiple punctures. As shown in Figure 1, a trend
toward an increasing FCT was shown in the two highest
rNAPc2 treatment groups, with a statistically significant
difference between the highest dose group (10.0 g/kg) and
placebo (median 16 min [IQR 10 to 28] and median 10 min
[IQR 10 to 14], respectively; p  0.001). Spearman
correlation showed a significant correlation between FCT
and rNAPc2 plasma levels at the moment of sheath removal
(r  0.317, p  0.001).
Clinical events. Clinical event rates were low and not
apparently related to the rNAPc2 dose. Intervention-related
MIs were observed in 10 patients (6% of total population).
Two patients experienced an acute MI after hospital dis-
charge. Bailout stent implantation was performed in two
patients, with four experiencing transient vessel closure
during the intervention. Two patients underwent coronary
artery bypass grafting, one of which was an emergency
procedure after PCI. There were two deaths: one due to
cardiogenic shock six days after the procedure and the other
due to a suspected cerebral vascular accident that occurred
one day after angioplasty. The clinical diagnosis of a cerebral
Table 1. Baseline Characteristics
Characteristic
Placebo
(n  30)
rNAPc2 Dose (g/kg)
3.5*
(n  23)
3.5
(n  24)
5.0
(n  24)
7.5
(n  27)
10.0
(n  26)
Age (yrs) 59  8 63  9 58  6 60  13 61  8 59  9
Male gender 67% 87% 92%† 79% 70% 85%
Previous MI 9 (30%) 8 (35%) 7 (29%) 8 (33%) 8 (30%) 8 (31%)
Previous PCI 4 (13%) 7 (30%) 3 (12%) 2 (8%) 9 (33%) 6 (23%)
Previous CABG 1 (3%) 2 (8%) 1 (4%) 3 (17%) 3 (11%) 1 (4%)
Single-vessel disease 17 (57%) 10 (43%) 14 (58%) 11 (46%) 18 (67%) 15 (58%)
Two-vessel disease 9 (30%) 7 (30%) 10 (42%) 12 (50%) 5 (19%) 7 (27%)
Three-vessel disease 4 (13%) 6 (26%) 0 1 (4%) 4 (15%) 4 (15%)
Body mass index (kg/m2) 28  4 27  3 28  4 28  3 26  3 26  2
Hypertension 9 (30%) 3 (13%) 6 (25%) 7 (29%) 5 (19%) 7 (27%)
Hypercholesterolemia 13 (43%) 10 (43%) 9 (37%) 10 (42%) 10 (37%) 9 (35%)
Diabetes 5 (17%) 1 (4%) 1 (4%) 2 (8%) 4 (15%) 4 (15%)
*No clopidogrel administration before PCI. †p  0.05 vs. placebo; chi-square analysis for categorical variables and Student t test
for continuous variables. Data are presented as the mean value  SD or number (%) of patients.
CABG  coronary artery bypass grafting; MI  myocardial infarction; PCI  percutaneous coronary intervention; rNAPc2 
recombinant nematode anticoagulant protein c2.
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vascular accident was not confirmed by a computed tomo-
graphic scan or autopsy. The patient had a history of
ischemic stroke. There were no arteriovenous fistulae or
femoral aneurysms. Differences in event rates between each
rNAPc2 treatment group and the placebo group were not
statistically significant.
Bleeding events. As presented in Table 3, there was no
difference between the first three rNAPc2 dosage levels and
placebo with respect to minor bleeding, varying from one to
three bleeding episodes per patient group. This incidence of
minor bleeding increased significantly to seven events in the
highest rNAPc2 dose group (p  0.01). The majority (n 
4) of these seven bleeding episodes were late rebleeds at the
site of sheath removal occurring 2 h after hemostasis.
There were four episodes of major bleeding, three of
which occurred in patients treated with 5.0 g/kg rNAPc2
(Table 3). The three incidents were classified as excessive
drainage after emergency bypass grafting, sustained oral
oozing after tracheal intubation, and a suspected cerebral
vascular accident. In addition to aspirin, UFH, and clopi-
dogrel, each of these three patients also received a GP
IIb/IIIa antagonist. Two received abciximab and one was
treated with tirofiban. It should be noted that two patients,
one each in the 3.5- and 7.5-g/kg dose groups, also
received a GP IIb/IIIa antagonist (both treated with epti-
fibatide) and had an uneventful outcome. The fourth major
hemorrhage was esophageal bleeding in a patient in the
7.5-g/kg dose group; this patient had esophagitis con-
firmed by endoscopy. This patient received aspirin, UFH,
and clopidogrel, but no GP IIb/IIIa antagonist.
Thrombin generation. Sixteen patients (10.4%) were ex-
cluded from the secondary outcome analysis because coro-
nary angiography was not followed by angioplasty (n  6),
PCI was performed 24 h after study drug administration (n
 1), a diagnosis of unstable angina was made just before
PCI (n 1), and either the GP IIb/IIIa antagonist or UFH
was administered after the procedure (n  8). As shown inTa
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Figure 1. Femoral compression time in minutes (median value and
interquartile range [IQR]) after sheath removal from the femoral artery.
*No clopidogrel administration before percutaneous coronary intervention.
The IQR of the 3.5* and 5.0 recombinant nematode anticoagulant protein
c2 (rNAPc2) dose groups is from 10 to 10 min. A comparison between the
placebo group and each rNAPc2 dose group was made by the Mann-
Whitney U test.
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Figure 2, F 12 plasma levels were lower in all treatment
groups during the procedure, coincident with UFH admin-
istration. A gradual 1.4-fold increase above preprocedural
levels of F12 was observed over the 30-h observation period
after the intervention in the placebo group only. There was
continued suppression of thrombin generation in all
rNAPc2 dose groups, which differed significantly from the
placebo group at 24 h to 36 h following a single subcuta-
neous administration. The extended duration of PCI in the
first 3.5-g/kg dose group did not affect these results.
The F12 results were mirrored by the levels of TAT
complexes, although this was statistically significant only at
the two highest doses at 36 h, most probably due to the wide
variation between the subjects (data not shown).
There was a dose-dependent increase in rNAPc2 plasma
levels. A weak inverse correlation was shown after PCI, at
12 and 24 h between plasma levels of rNAPc2 and the
thrombin generation markers F12 and TAT complexes.
However, this became statistically significant for both mark-
ers at 36 h (r  0.300 and r  0.439, respectively; p 
0.01). Figure 3 presents the inverse relation between
rNAPc2 plasma levels and thrombin generation, as mea-
sured by F12, at 36 h.
DISCUSSION
In patients with stable angina undergoing planned coronary
stent implantation, the composite of death, MI, urgent
target vessel revascularization, and bailout GP IIb/IIIa
inhibitor therapy has been reported to occur in7% of cases
within 48 h (12). The composite of death, MI, and urgent
target vessel revascularization increases to 9% to 13% within
48 h after PCI in patients with unstable coronary syndromes
(13,14). The TF/factor VIIa complex plays a pivotal role in
initiating the thrombotic response to vascular injury (3),
which makes this enzymatic complex a target for the
development of anticoagulant strategies for patients with
coronary thrombosis. Our study demonstrates that inhibi-
tion of the TF/factor VIIa complex by a single subcutaneous
dose of rNAPc2, administered before elective coronary
angioplasty, is safe in combination with aspirin, clopidogrel,
and UFH and produces a prolonged and significant sup-
pression of thrombin generation.
Bleeding events. Overall, rNAPc2 was well tolerated with
respect to the incidence of major and minor bleeding
episodes. However, of four major bleedings, three occurred
in patients in the 5.0-g/kg dose group at the time they also
Table 3. Incidence of Bleeding
Placebo
(n  30)
rNAPc2 Dose (g/kg)
3.5*
(n  23)
3.5
(n  24)
5.0
(n  24)
7.5
(n  27)
10.0
(n  26)
Minor bleeding 2 (6.7%) 2 (8.7%) 1 (4.2%) 1 (4.2%) 3 (11.1%) 7 (26.9%)†
Major bleeding 0 0 0 3 (12.5%)† 1 (3.7%) 0
*No clopidogrel administration before percutaneous coronary intervention. †p  0.05 vs. placebo; chi-square analysis. Data are
presented as the number (%) of patients.
rNAPc2  recombinant nematode anticoagulant protein c2.
Figure 2. Mean values (SEM) of prothrombin activation fragment 12 plasma levels for the placebo and recombinant nematode anticoagulant protein
c2 (rNAPc2) dose groups. †No clopidogrel treatment before percutaneous coronary intervention. The following statistically significant differences were
found between the rNAPc2 dose groups and placebo (Bonferroni-corrected p values, including five comparisons at each time point): *p  0.05: 3.5† and
3.5 vs. placebo; p  0.01: 7.5 vs. placebo; **p  0.05: 5.0 vs. placebo; p  0.01: 3.5† vs. placebo; p  0.001: 3.5, 7.5, and 10.0 vs. placebo; ***p  0.05:
3.5†, 3.5, and 5.0 vs. placebo; p  0.001: 7.5 and 10.0 vs. placebo. Solid diamond  placebo; open square  3.5† g/kg;   3.5 g/kg; solid triangle
 5.0 g/kg; open triangle  7.5 g/kg; open circle  10.0 g/kg.
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received a GP IIb/IIIa antagonist. Two more patients also
received GP IIb/IIIa antagonists and did not experience
bleeding. Because the number of observations in patients
receiving the combination of rNAPc2 and GP IIb/IIIa
antagonists is small, no conclusion can be drawn regarding
the safety of this combination. Therefore, additional safety
data from future trials in which rNAPc2 and GP IIb/IIIa
antagonists are used concomitantly will be required before
we can define how these strategies can be optimally used in
the treatment of patients. The effects of rNAPc2 during
coronary bypass surgery remain to be evaluated, as only two
study patients underwent this procedure after receiving
rNAPc2. As expected, there was a higher incidence of
minor bleeding episodes in the two highest dose groups,
with a statistically significant difference between the 10.0-
g/kg and placebo groups. The majority of minor bleedings
in the 10.0-g/kg dose group were late rebleeds at the
catheter access site, consistent with the prolonged antico-
agulant effect of rNAPc2. Although recombinant factor
VIIa has been shown to transiently reverse the anticoagulant
effects of rNAPc2 in normal volunteers (15), there were no
incidents of severe bleeding that required its use.
Femoral compression time. In patients undergoing car-
diac catheterization, bleeding after sheath removal at the
arterial puncture site is a form of controlled surgical bleed-
ing that may be quantified, similar to the conventional
bleeding time according to Mielke and Rodvien (16). To
this end, we standardized sheath removal and quantified the
time required to complete hemostasis by using a protocol-
driven procedure. In our study, the FCT was prolonged in
the 7.5- and 10.0-g/kg dose groups, with a statistically
significant difference between the latter group and the
placebo group. Although little inter-individual variation
may persist, despite a structured protocol, these data still
suggest a dose-dependent prolongation, as well as an ap-
parent effect on clinical hemostasis at the two highest doses
of rNAPc2. In addition, there was a significant correlation
between FCT and rNAPc2 plasma levels at the time of
sheath removal. Systemic F12 and TAT complex plasma
levels were already maximally suppressed at the lowest dose
of rNAPc2, and there was no correlation between these
plasma markers and FCT. Clearly, hemostasis involves
contributions of the arterial wall, platelets, and coagulation,
and systemic coagulation marker plasma levels may not
completely reflect this process. Thus, based on our findings,
the FCT may provide clinically relevant quantitative infor-
mation. Indeed, this must be confirmed in future trials.
Thrombin generation. Although the patients enrolled in
this study were not considered to be at high risk, in the
placebo group, we observed a marked and sustained eleva-
tion of thrombin generation, as measured by plasma levels of
F12, to above preprocedural levels up to at least 30 h after
PCI. In contrast, thrombin generation continued to be
suppressed in all of the rNAPc2 treatment groups, which
was sustained through the last sampling time point at 36 h.
These data suggest that the ongoing thrombin generation
observed in the placebo group following the procedure was
effectively suppressed by rNAPc2. Plasma levels of TAT
complexes, used as another measure of thrombin generation,
showed, as expected, a similar response as that found for
F12. Thus, TF/factor VIIa may play an important role in
the process of ongoing thrombosis after PCI, as suggested
recently in high-risk patients with unstable coronary syn-
dromes (17), and rNAPc2 appears to effectively suppress
this process.
Unfractionated heparin and low-molecular-weight hepa-
rins are widely used for the treatment of patients with acute
coronary syndromes or those undergoing PCI. A synthetic
pentasaccharide (fondaparinux), which may serve as an
alternative for both drugs, is currently undergoing clinical
development in these patient populations (18,19). However,
it should be noted that although these agents should
theoretically attenuate thrombin generation via the inhibi-
tion of factor Xa assembled in the prothrombinase complex
(i.e., factor Va, negatively charged membrane surfaces, and
calcium ions), the dependence on antithrombin III may
limit their effectiveness in situations where there is a high
level of prothrombinase activity, such as at the site of an
atherosclerotic plaque rupture, because it has been shown
that antithrombin III–dependent inhibitors, including he-
parins of any molecular size, do not effectively inhibit factor
Xa assembled in the prothrombinase complex (20). There-
fore, this may explain the reduced antithrombotic potential
of these agents in suppressing the thrombogenicity of
coronary lesions leading to clinical events during or shortly
after early therapy (21,22). In contrast, the inhibition of
TF/factor VIIa complex-mediated generation of factor Xa
and subsequently thrombin by rNAPc2 is enhanced follow-
ing the assembly of the TF/factor VIIa complex (9).
Therefore, rNAPc2 has the potential advantage of attenu-
Figure 3. Plasma levels of recombinant nematode anticoagulant protein c2
(rNAPc2) in relation to plasma levels of prothrombin activation fragment
12 (F12) at 36 h.
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ating the highly amplified formation of thrombin by inhib-
iting the coagulation cascade at a more proximal site relative
to direct inhibitors of factor Xa and thrombin, and thus may
offer a more effective approach to reducing thrombosis in
patients with coronary artery disease.
Optimal rNAPc2 dose. As mentioned, the suppression of
plasma levels of F12 and TAT complexes by rNAPc2 was
already maximal at the lowest dose (3.5 g/kg). The
significant inverse correlations between plasma levels of
rNAPc2 and each of these two markers at 36 h indicate that
the two highest doses of rNAPc2 result in a more sustained
suppression of both markers, compared with the lower doses
(Figs. 2 and 3). However, the usefulness of the systemic
markers of thrombin generation in assessing the clinical
efficacy of rNAPc2 could not be determined in this study.
The effect of rNAPc2 on the observed clinical bleeding
complications suggests that the optimal and sufficiently safe
dose of rNAPc2, when combined with aspirin, clopidogrel,
and UFH, is likely to be 10.0 g/kg. This is consistent
with the significant prolongation of FCT at the highest
dose.
Conclusions. Our study indicates that inhibition of the
TF/factor VIIa complex at doses up to 7.5 g/kg of
rNAPc2, in combination with aspirin, clopidogrel, and
UFH, appears to be a safe and effective strategy to prevent
thrombin generation in patients undergoing a catheter-
based coronary intervention. These results are supportive of
advancing rNAPc2 into a phase II, dose-ranging trial in
patients with unstable angina or non–Q-wave MI.
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